One of the most common questions international buyers ask about Indian generic medicines is: “How do I know the quality is real?” The answer lies in the rigorous, multi-stage laboratory testing that every batch of medicine undergoes before it reaches the market. Understanding this testing framework can help buyers make informed decisions and evaluate suppliers with confidence.
India is the world’s largest supplier of generic medicines by volume, accounting for approximately 20% of global generic drug exports (Pharmexcil, 2025–26 data). This scale is supported by a comprehensive quality testing infrastructure that includes over 1,400 NABL-accredited pharmaceutical testing laboratories and CDSCO-approved government testing facilities across the country.
🔄 The Quality Testing Journey: From Raw Material to Finished Product
Every batch of generic medicine in India passes through four distinct testing stages before it is released for sale:
- Stage 1 — Raw Material (API) Testing: Every incoming batch of Active Pharmaceutical Ingredient (API) is tested for identity, purity, potency, and impurities before manufacturing begins. Rejected APIs never enter production.
- Stage 2 — In-Process Quality Control (IPQC): During manufacturing, samples are taken at critical steps — blending, granulation, compression, coating — to ensure the product meets specifications at every stage.
- Stage 3 — Finished Product Testing: The completed batch undergoes full pharmacopoeial testing: assay, dissolution, uniformity of content, impurity profiling, and microbial limits.
- Stage 4 — Batch Release and Stability Testing: Only batches that pass all tests receive a Certificate of Analysis (CoA). Retained samples undergo real-time and accelerated stability studies to confirm shelf life.
This four-stage system is mandated under Schedule M of India’s Drugs and Cosmetics Rules, which codifies WHO-GMP standards into Indian law. The CDSCO enforces compliance through regular inspections and audits (cdsco.gov.in).
🧪 Key Quality Tests Every Batch Must Pass
Indian manufacturers test each batch against the specifications of the relevant pharmacopoeia — typically the Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), or United States Pharmacopeia (USP). Here are the most important tests:
- Assay (Potency Test): Measures the concentration of the active ingredient. A 500 mg paracetamol tablet must contain between 95.0% and 105.0% of the labelled amount (IP specification).
- Dissolution Test: Determines how quickly the drug releases its active ingredient in simulated digestive fluids. This is the single most important test for predicting how the medicine will perform in the body.
- Uniformity of Content/Dosage Units: Ensures each tablet or capsule in a batch contains the same amount of active ingredient — critical for drugs with narrow therapeutic windows.
- Related Substances / Impurity Profiling: Detects degradation products, process impurities, and residual solvents. Limits are set by ICH Q3 guidelines.
- Disintegration Test: Confirms that tablets break apart within a specified time (typically 15-30 minutes for uncoated tablets).
- Microbial Limits Testing: Checks for bacteria, yeast, mould, and specified pathogens (E. coli, Salmonella, S. aureus, Pseudomonas aeruginosa).
- Sterility Testing (for injectables): Parenteral products must pass sterility tests per IP/USP/EP methods.
According to the Indian Pharmacopoeia Commission, manufacturers are required to retain batch samples for at least one year beyond the expiry date to enable re-testing if quality concerns arise.
🔬 Active Pharmaceutical Ingredient (API) Testing
The quality of the finished medicine depends directly on the quality of the API. India is a leading producer of APIs, supplying approximately 57% of the world’s API demand (excluding China’s share). API testing includes:
- Identification — FTIR, HPLC retention time, or melting point confirmation
- Assay — Purity determination by HPLC or UV spectrophotometry (typically 98.0%-102.0%)
- Heavy Metals — Limits for lead, arsenic, mercury, cadmium, etc. (ICH Q3D)
- Residual Solvents — GC testing per ICH Q3C classifications
- Polymorph Purity — X-ray diffraction (XRD) to confirm the correct crystalline form
Buyers should request the API’s Drug Master File (DMF) reference and confirm that the API supplier itself is WHO-GMP or EU-GMP certified. Reputable Indian manufacturers source APIs only from approved vendors who supply a Certificate of Analysis with every batch.
⏱ Dissolution Testing: The Bioavailability Predictor
Dissolution testing is arguably the most critical quality control test for solid oral dosage forms (tablets and capsules). It measures how much of the active ingredient is released into solution over time under controlled conditions.
The test uses USP Apparatus 1 (basket) or USP Apparatus 2 (paddle) at 37°C in specified dissolution media (pH 1.2, 4.5, or 6.8 buffer solutions simulating digestive tract conditions). The typical specification is Q = 80% — meaning at least 80% of the labelled active ingredient must be dissolved within a specified time (usually 30–45 minutes).
For generic medicines, dissolution profiles are compared against the innovator (brand-name) product in bioequivalence studies (f2 similarity factor ≥ 50). This ensures the generic medicine releases the drug at the same rate and extent as the original. CDSCO mandates comparative dissolution data for all generic drug approvals in India (CDSCO guidance document).
📄 Understanding the Certificate of Analysis (CoA)
The Certificate of Analysis (CoA) is the single most important document a buyer can request from their supplier. A complete CoA should contain:
- Product name, batch number, and manufacturing date
- Expiry date and batch size
- Reference pharmacopoeia (IP, USP, BP, or EP)
- List of tests performed with specifications and actual results
- Date of testing and analyst signature
- QA/QC manager authorisation with stamp
- NABL accreditation number of the testing laboratory
A CoA from a NABL-accredited lab carries significant weight. The National Accreditation Board for Testing and Calibration Laboratories (NABL) is India’s equivalent of ISO/IEC 17025 accreditation and is recognised by the International Laboratory Accreditation Cooperation (ILAC) through mutual recognition arrangements (nabl.qci.org.in).
⚠️ Red Flag: If a supplier refuses to provide a CoA for a specific batch, or if the CoA lacks a laboratory reference number, this is a strong indicator that the product may not have undergone proper testing. Legitimate manufacturers make batch CoAs available upon request as a standard practice.
🏭 NABL-Accredited Testing Laboratories in India
As of 2026, India has over 1,400 NABL-accredited pharmaceutical testing laboratories, including both government facilities and private third-party labs. Key facilities include:
- Central Drugs Laboratory (CDL), Kolkata — India’s national control laboratory and WHO-prequalified
- Regional Drug Testing Laboratories (RDTLs) in Mumbai, Chennai, Hyderabad, Guwahati, and other cities
- State Drug Control Laboratories under respective State FDAs
- Private third-party labs such as SGS India, TUV Rheinland, Intertek, and numerous independent NABL-accredited facilities
In addition to batch release testing, CDSCO conducts random surveillance sampling of marketed drugs each year. Samples are drawn from pharmacies, distribution centres, and manufacturing facilities for independent testing at government labs. Under India’s “Jan Aushadhi” initiative, samples from Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) stores — which sell quality generics at affordable prices — are tested regularly to maintain public confidence.
🌍 How Indian Testing Standards Compare Globally
Indian pharmacopoeial standards (IP) are closely harmonised with international standards. In most cases, the IP monograph for a drug substance or product uses the same or equivalent test methods and limits as the USP or BP. Key points of comparison:
- Assay limits: Typically 95.0%-105.0% for finished products — consistent with USP and BP
- Dissolution specifications: Q = 80% in 30-45 minutes for immediate-release products — same as international norms
- Impurity limits: Follow ICH Q3A/Q3B guidelines for identification and qualification thresholds
- Microbial limits: Match USP <61>/<62> and EP 2.6.12/2.6.13 methods
- Stability testing: Follows ICH Q1A (R2) guidelines — 25°C/60% RH for long-term, 40°C/75% RH for accelerated
For products exported to regulated markets (US, EU, UK, Australia, Japan), Indian manufacturers must also meet the specific pharmacopoeial and GMP requirements of the destination country — and are inspected by the respective regulatory agencies (US FDA, MHRA, TGA, PMDA) for approval.
✅ Practical Quality Checklist for Buyers
When evaluating an Indian generic medicine supplier, request and verify the following:
- ✓ WHO-GMP Certificate: Issued by CDSCO or State FDA — verify validity on the CDSCO portal
- ✓ Batch-specific Certificate of Analysis (CoA): Must be from a NABL-accredited laboratory
- ✓ Stability study data: Should include both long-term (25°C) and accelerated (40°C) conditions
- ✓ Manufacturing licence: Issued by the State FDA under the Drugs and Cosmetics Act, 1940
- ✓ Drug Master File (DMF): If the product is exported to regulated markets
- ✓ Third-party audit reports: Many reputable manufacturers welcome buyer audits or share recent inspection findings from regulators
For a list of verified and reliable pharmaceutical distributors who adhere to these quality standards, refer to the IMSDA’s verified member directory.
For more information, contact IMSDA at contact@indiamedicine.org.